Hyperpol big typo3

Preclinical Hyperpolarized Carbon-13 Magnetic Resonance Imaging in Neurological Disease Models

Hyperpolarized (HP)-13C MR provides dramatically higher molecular sensitivity in metabolic imaging by increasing the signal-to-noise ratio of HP 13C-labelled probes by a factor of up to 50,000. The technology has been widely applied to cancer research, but, more recently, it is proven as a viable tool for imaging of neurological disorders often associated with inflammatory processes, as well as other non-cancerous applications.
This webinar took place on November 21st 2019

Register to download slides & media

Overview

In this webinar, Dr. Myriam Chaumeil from the University of California, San Francisco, will discuss emerging applications for HP-13C MRI in detection of inflammatory cells, such as macrophages, involved in neuroinflammation in various preclinical models, and the potential for this method to fill current gaps in clinical imaging techniques currently available.

The metabolic reprogramming that occurs when inflammatory cells are activated as part of the immune response can be targeted by HP-13C probes in a manner similar to techniques imaging metabolically active cancer cells. This resemblance prompted Chaumeil and colleagues to evaluate the technique for the detection and monitoring of neuroinflammation in cells (e.g. macrophages) and various diseases models, including multiple sclerosis, traumatic brain injury, and Alzheimer’s disease.

What to expect

Data on models of neurological conditions will be presented, as well as a review of what other researchers in the field have been doing. Bruker’s Preclinical BioSpec 3T operating with a cryogen-free magnet, will be introduced, as will plans to develop new probes and translate the methodology to the clinic in the future.

Key topics

  • The technology’s potential to improve diagnosis and therapeutic response in various non-cancer neurological diseases
  • Detecting lesions in multiple sclerosis and potentially differentiating disease subtypes
  • Potential to detect trauma early on in traumatic brain injury
  • Potential to diagnose Alzheimer’s early in disease course
  • Fundamental concepts of HP-13C MR
  • Current advantages of using the BioSpec 3T and plans to develop new hyperpolarized probes with long lifetimes

Who should attend?

This webinar would appeal to pre-clinical researchers, people interested in imaging neurological disorders and neuroscientists who are working in industry or academia. It would also appeal to clinicians interested in potential future applications and scientists involved in novel MRI applications.

Speakers

Todd Sasser, PhD
Todd Sasser, PhD
Head of Applications PCI, Americas Bruker BioSpin Billerica, Massachusetts
Todd Sasser is a Field Applications Scientist for Bruker Preclinical Imaging. He provides application support for in vivo imaging across a wide variety of disciplines from infection imaging, cancer biology, and probe development. He currently focuses on application development for the Albira PET/SPECT/CT system. Dr. Sasser studied at The University of Liverpool and The University of Hawaii and is currently a visiting scholar at The University of Notre Dame.
Dr. Myriam Chaumeil
Dr. Myriam Chaumeil
Assistant Professor in residence Department of Physical Therapy and Rehabilitation Science Department of Radiology and Biomedical Imaging University of California, San Francisco (UCSF)
Myriam M. Chaumeil, PhD, is an Assistant Professor of Physical Therapy and Rehabilitation Science, and Radiology and Biomedical Imaging at UCSF. Her research focuses on developing MRI/S methods, especially based on hyperpolarized 13C MR, for in vivo assessment of healthy and diseased brain metabolism (e.g. lymphomas, Multiple Sclerosis, Alzheimer’s, Trauma).